Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study

Danielle M. Gerlag, Mary Safy, Karen I. Maijer, Man Wai Tang, Sander W. Tas, Mirian J. F. Starmans-Kool, Astrid van Tubergen, Matthijs Janssen, Maria de Hair, Monika Hansson, Niek de Vries, Aeilko H. Zwinderman, Paul P. Tak*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)179-185
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume78
Issue number2
DOIs
Publication statusPublished - Feb 2019

Keywords

  • SEROPOSITIVE ARTHRALGIA
  • TARGETED THERAPY
  • RISK-FACTORS
  • DISEASE
  • RITUXIMAB
  • AUTOANTIBODIES
  • METHOTREXATE
  • INDIVIDUALS
  • INDUCTION
  • EFFICACY

Cite this

Gerlag, D. M., Safy, M., Maijer, K. I., Tang, M. W., Tas, S. W., Starmans-Kool, M. J. F., van Tubergen, A., Janssen, M., de Hair, M., Hansson, M., de Vries, N., Zwinderman, A. H., & Tak, P. P. (2019). Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Annals of the Rheumatic Diseases, 78(2), 179-185. https://doi.org/10.1136/annrheumdis-2017-212763